PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells

被引:19
|
作者
Russo, Debora [1 ]
Ottaggio, Laura [2 ]
Penna, Ilaria [1 ]
Foggetti, Giorgia [1 ]
Fronza, Gilberto [1 ]
Inga, Alberto [3 ]
Menichini, Paola [1 ]
机构
[1] Natl Canc Res Inst IST, Dept Epidemiol & Prevent, Mol Mutagenesis & DNA Repair Unit, I-16132 Genoa, Italy
[2] Natl Canc Res Inst IST, Dept Adv Diagnost Tech, Cytogenet Unit, I-16132 Genoa, Italy
[3] Univ Trento, Ctr Integrat Biol CIBIO, I-38060 Trento, Italy
关键词
PRIMA-1; Mutant p53; Nucleolus; p53; degradation; ubiquitylation; Breast cancer; IN-VITRO; TRANSCRIPTION; RESTORATION; GROWTH; VIVO; STABILIZATION; REACTIVATION; ACTIVATION; APOPTOSIS; MUTATION;
D O I
10.1016/j.bbrc.2010.10.031
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PRIMA-1 has been identified as a compound that restores the transactivation function to mutant p53 and induces apoptosis in cells expressing mutant p53. Studies on subcellular distribution of the mutant p53 protein upon treatment with PRIMA-1(Met), a methylated form of PRIMA-1, have suggested that redistribution of mutant p53 to nucleoli may play a role in PRIMA-1 induced apoptosis. Here, we specifically investigated the influence of PRIMA-1 on cellular localization of mutated p53-R280K endogenously expressed in tumour cells. By using immunofluorescence staining, we found a strong nucleolar redistribution of mutant p53 following PRIMA-1 treatment. This subcellular localization was associated to p53 degradation via ubiquitylation. When cells were treated with adriamycin, neither nucleolar redistribution nor mutant p53 down modulation and degradation were observed. Interestingly, cells where p53-R280K was silenced were more sensitive to PRIMA-1 than the parental ones. These results indicate that in some cellular context, the cell sensitivity to PRIMA-1 could depend on the abolition of a gain-of-function activity of the mutated p53, through a protein degradation pathway specifically induced by this compound. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:345 / 350
页数:6
相关论文
共 50 条
  • [21] A Chimeric p53 Evades Mutant p53 Transdominant Inhibition in Cancer Cells
    Okal, Abood
    Mossalam, Mohanad
    Matissek, Karina J.
    Dixon, Andrew S.
    Moos, Philip J.
    Lim, Carol S.
    MOLECULAR PHARMACEUTICS, 2013, 10 (10) : 3922 - 3933
  • [22] Modulation of p53 transcriptional activity by PRIMA-1 and Pifithrin-α on staurosporine-induced apoptosis of wild-type and mutated p53 epithelial cells
    J. F. Charlot
    M. Nicolier
    J. L. Prétet
    C. Mougin
    Apoptosis, 2006, 11 : 813 - 827
  • [23] Modulation of p53 transcriptional activity by PRIMA-1 and Pifithrin-α on staurosporine-induced apoptosis of wild-type and mutated p53 epithelial cells
    Charlot, J. F.
    Nicolier, M.
    Pretet, J. L.
    Mougin, C.
    APOPTOSIS, 2006, 11 (05) : 813 - 827
  • [24] C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In Vivo
    Fine, Robert L.
    Mao, Yuehua
    Dinnen, Richard
    Rosal, Ramon V.
    Raffo, Anthony
    Hochfeld, Uri
    Senatus, Patrick
    Bruce, Jeffrey N.
    Nichols, Gwen
    Wang, Hsin
    Li, Yongliang
    Brandt-Rauf, Paul W.
    BIOMEDICINES, 2023, 11 (01)
  • [25] PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
    Perdrix, Anne
    Najem, Ahmad
    Saussez, Sven
    Awada, Ahmad
    Journe, Fabrice
    Ghanem, Ghanem
    Krayem, Mohammad
    CANCERS, 2017, 9 (12):
  • [26] Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53:: Necrosis vs. apoptosis
    Cory, AH
    Chen, JM
    Cory, JG
    ANTICANCER RESEARCH, 2006, 26 (2A) : 1289 - 1295
  • [27] PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis
    Zaza, Mohamed
    Rashed, Mohammed H.
    Elrefaey, Hesham
    Hassan, Memy H.
    Abo-Salem, Osama M.
    El-Sayed, El-Sayed M.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (01) : 55 - 68
  • [28] Mutant p53 reactivators protect breast cancer cells from ferroptosis
    Rathnayake, Dewmi Sandaru
    Dlamini, Samkeliso
    Elkalawozgy, Kadry
    Tillekeratne, L. M. Viranga
    Taylor, William R.
    CELL BIOCHEMISTRY AND FUNCTION, 2024, 42 (04)
  • [29] Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells
    Zhang, Wei
    Yi, Bin
    Wang, Chao
    Chen, Dongquan
    Bae, Sejong
    Wei, Shi
    Guo, Rong-Jun
    Lu, Changming
    Nguyen, Lisa L. H.
    Yang, Wei-Hsiung
    Lillard, James W.
    Zhang, Xingyi
    Wang, Lizhong
    Liu, Runhua
    CLINICAL CANCER RESEARCH, 2016, 22 (10) : 2545 - 2554
  • [30] Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
    Duffy, Michael J.
    Synnott, Naoise C.
    Crown, John
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (02) : 213 - 219